Contract facts
FederalNo full NAICS 541380 intel page yet. Browse NAICS intelligence
GENOMIC ANALYSIS is a federal award for Rpo East (36C24E) held by Akesogen, Inc. Estimated value $13M ($13M obligated). Current period of performance ends Sep 29, 2023. Place of performance: WASHINGTON DC.
Recompete timing
PublicCurrent PoP ended Sep 29, 2023 (1057 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C24E22N0189?
36C24E22N0189 (Genomic analysis) is a Rpo East (36C24E) award with a potential value of $13M, currently held by Akesogen, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C24E-22-N-0189?
36C24E-22-N-0189 is the dashed form of PIID 36C24E22N0189 (Genomic analysis), held by Akesogen, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C24E22N0189?
Rpo East (36C24E) awarded 36C24E22N0189 to Akesogen, Inc (potential $13M).
Who is the incumbent on 36C24E22N0189?
Akesogen, Inc is the incumbent. The current period of performance ends Sep 29, 2023.
When does Akesogen, Inc’s 36C24E22N0189 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 29, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.